|
Post by mnkdfann on Mar 6, 2021 19:06:31 GMT -5
As noted in the EYEs threads, though, that business combination (is it fair to call it a buyout, I'm not sure) isn't particularly advantageous to EYES shareholders. Sure looks to be a good deal for shareholders of Pixium, though.
|
|
|
Post by mnkdfann on Mar 3, 2021 2:27:22 GMT -5
Another (good) way to consider events of the past 2 days is realization that share price is still (barely) above it's close exactly one month ago. Likewise, nothing of great significance has changed regarding MNKD during that month, except securing $200 million (or $300 million if Danbury plant sale/leaseback still happens). Therefore, in words of a longtime ProBoards poster: "Let's Roll". MNKD life is finally getting sustainably better (IMHO). So, you say the share price is back to where it was a month ago, and the company is now saddled with hundreds of millions of dollars of new debt? When you put it like that, I'm even more thankful that the SP has not fallen further.
|
|
|
Post by mnkdfann on Mar 1, 2021 21:20:57 GMT -5
Fingers crossed, BTIG / Schwab / Wainwright's very recent comments have/had nothing to do with the private placement (i.e. they weren't selling their book, or hustling to get in on the deal).
|
|
|
Post by mnkdfann on Mar 1, 2021 10:35:18 GMT -5
My question is why they would “pre-announce” this offering and let the stock price drift down 10%? Why wouldn’t they just announce it when they could disclose the terms and had the investors locked in? Is there an SEC requirement to announce intentions? I can't say that EVERY company does it this way, but it seems whenever any company I watch issues such offerings they 'pre-announce' it this way. That leads me to believe there must be some SEC requirement. But I dunno for certain.
|
|
|
Post by mnkdfann on Feb 24, 2021 11:26:42 GMT -5
|
|
|
Post by mnkdfann on Feb 15, 2021 18:25:42 GMT -5
Wasn't the meeting yesterday? Was it any good? Did Josh and Eric do a good job? One guy was asking about blacks and Afrezza if they had any information on that..they were kinda taken off guard by the ask....I noted "Isn't Damen Dash was on it ?" That seemed to make the guy happy..I mean..Damen knows a lot about it..check his network..he's like on it..oh and O explained the lower risk of hypo and why..and the zero carb study with zero hypo's There appears to be evidence that blacks suffer disproportionately from some inhaled (e.g. asthma) medications, so perhaps that is where that question was coming from. www.sciencedaily.com/releases/2019/09/190927135119.htmwww.webmd.com/asthma/news/20060112/asthma-drug-may-be-deadlier-for-blacksI wasn't aware that Dash was even talking about Afrezza anymore (seems like a long time since he was actively promoting it) but, surprise, he did give Afrezza a shout out quite recently: thegrio.com/2020/12/22/damon-dash-diabetes-covid-vaccine-interview/
|
|
|
Post by mnkdfann on Feb 14, 2021 15:14:04 GMT -5
IMO, it barely registers as news. It is clickbait, trying to sell a product.
As the 'article' itself says (and this is basically all the article says): "This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading."
|
|
|
Post by mnkdfann on Feb 12, 2021 15:03:29 GMT -5
I'd like to apply the title of this thread, "What is going on?" to MNKD options today. Maybe it's just a glitch on TDA, but my January 10 calls are showing a bid/ask of 1.20 / 5.00 (a few minutes later, 1.20 and 3.20) and TDA is saying value has been up between 80% and 166% (depending on when you looked). Now historically, TDA's option value change reporting has been less than meaningful, but not off by this much from what I'd expect. All I can think of is the rumor of a Tuesday squeeze is somehow affecting the option pricing? Any ideas? Dunno. I see 1.20 to 2.10 as the range, and reported value up by about 13%, on BMO Investorline.
|
|
|
Post by mnkdfann on Feb 10, 2021 19:29:19 GMT -5
|
|
|
Post by mnkdfann on Feb 9, 2021 18:26:32 GMT -5
Didn’t we build an addition in Danbury: accordingly Exactly. That's MNKD's plant. If UTHR wants to do the production itself (and IIRC that is its right, someone correct me if I am mistaken), presumably it would want its own plant.
|
|
|
Post by mnkdfann on Feb 9, 2021 17:58:31 GMT -5
Is it just me, or is that second photo (view of the partially demolished building) not reminiscent of an All Terrain Armored Transport, or AT-AT walker, from Star Wars?
Anyway, sure, hope this means big things for MNKD. Maybe that overall confidence of UTHR is being reflected in the MNKD share price?
|
|
|
Post by mnkdfann on Jan 30, 2021 0:08:56 GMT -5
Dated 12/31/2020. So, they now own 7.6%. They have been invested, so, did they just buy more? I wonder how much more? M ore long-term holders are good.Sure, but they're not a new long term holder. They've been invested since at least 2014. There is generally a new thread like this one every year, sometimes more than once a year. Google the two words mannkind blackrock and you'll find them. Here is one from 2014: mnkd.proboards.com/thread/1446/ownership-tracking-shares-options
|
|
|
Post by mnkdfann on Jan 19, 2021 10:21:14 GMT -5
I guess things are starting to happen in earnest at RLS. New CEO...New homepage (again)... www.receptorlife.com/Oddly, they’ve gone out of their way to hide the URLs of their website pages and only present the main URL. Check out their press releases. It’s news as of today, 1/19/2021. JAN 19, 2021 | Press Release Receptor Life Sciences Names Successful Pharmaceutical Industry Executive, Mark Theeuwes, President and Chief Executive Officer SEATTLE – Receptor Life Sciences ("RLS") today announced the appointment of Mark Theeuwes as President, Chief Executive Officer and member of the Board of Directors of RLS. Mr. Theeuwes will succeed Greg Wesner, who co-founded Receptor in 2015 and has served as CEO and Director since its inception. Mr. Wesner will remain on the Board of Directors of RLS. "RLS is at an important inflection point with our delivery technologies expected to have INDs in 2021. Mark is an experienced pharmaceutical executive with a proven track record of building clinical and commercial stage organizations. Under Mark’s leadership, RLS is well-positioned for continued success," said Arthur Rubinfeld, Executive Chairman of RLS. Mr. Theeuwes joins RLS following the acquisition of Engage Therapeutics ("Engage") by UCB in June 2020. He served as Chief Operating Officer from 2018 until its acquisition, which came following positive data from a large, randomized Phase 2 clinical trial of its lead product candidate in development for a new product category called REST (Rapid Epileptic Seizure Termination). Prior to joining Engage, Mr. Theeuwes held positions of increasing responsibility at Egalet, NPS (acquired by Shire), ViroPharma (acquired by Shire), OraPharma (acquired by Valeant), Johnson & Johnson and Alza (acquired by J&J). "I am honored and excited to lead RLS and build upon the solid foundation that Greg and the team have established over the last five years," said Mr. Theeuwes. "Receptor has two promising clinical candidates in its pipeline that may favorably impact millions of patients who today have inadequate therapies. I look forward to progressing the pipeline to bring these therapies to patients in need." Contact for Media: Mark Theeuwes mtheeuwes@receptorlife.com As far as I can tell this “PR” was not put out on the wire for the media. Wasn't too hard to find, it was out for the media as of at least 8 am EST: www.businesswire.com/news/home/20210119005088/en/Receptor-Life-Sciences-Names-Successful-Pharmaceutical-Industry-Executive-Mark-Theeuwes-President-and-Chief-Executive-Officer
|
|
|
Post by mnkdfann on Jan 18, 2021 16:04:41 GMT -5
"This activity is supported by an educational grant from MannKind." Hey, so better than even odds they may mention Afrezza!
|
|
|
Post by mnkdfann on Jan 16, 2021 13:05:48 GMT -5
Did you read the same article I did? I might have missed something, but what I saw doesn't support what you said. "Our analysis also showed that adult trials actually have a lower cost per procedure than pediatric trials." "For the 2006-09 timeframe, the pediatric cost per procedure was actually 7% higher than for that of adult clinical trials and 50% higher for the 2010-13 timeframe." Over the study period not only were paediatric trials MORE expensive, but they were becoming increasingly more-so.
|
|